10 completed, 1 terminated. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow EDP-938: new trials by email Literature Review of EDP-938 trials Research Report on EDP-938
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo - RSV Infection, QTc Interval | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2024-07-15 | 2025-07-28 |
| A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. EDP-938, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 187 | 2022-11-29 | 2026-08-19 |
| A Study to Evaluate EDP 938 Regimens in Children With RSV EDP-938, Placebo - Respiratory Syncytial Virus (RSV) | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 99 | 2022-04-26 | 2025-07-28 |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract EDP-938, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Enanta Pharmaceuticals, Inc | 9 | 2021-07-07 | 2024-08-22 |
| Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects EDP-938 - Respiratory Syncytial Virus (RSV) | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 8 | 2021-05-28 | 2022-03-23 |
| Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects EDP-938, Fluconazole - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2021-03-12 | 2021-05-04 |
| Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects EDP-938, Tacrolimus, Dabigatran - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 89 | 2020-07-08 | 2021-10-13 |
| A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects EDP-938, Placebo - Respiratory Syncytial Virus | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 82 | 2020-01-22 | 2023-10-30 |
| Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects EDP-938, Itraconazole, Rifampin - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2018-11-29 | 2019-06-14 |
| Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects EDP-938, Cyclosporine, Prednisone - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2018-11-02 | 2019-02-12 |
| A Study of EDP-938 in Healthy Subjects EDP-938, Placebo - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 90 | 2017-12-07 | 2018-10-10 |
Respiratory Syncytial Virus Infections (8)
Enanta Pharmaceuticals, Inc (11)
United States (11) · Argentina (4) · Poland (4) · South Africa (4) · Mexico (3) · Spain (3) · Taiwan (3) · Brazil (2) · Bulgaria (2) · Colombia (2) · Israel (2) · New Zealand (2) · South Korea (2) · United Kingdom (2) · Australia (1)